P70S6 kinase phosphorylation for pharmacodynamic monitoring

Clinica Chimica Acta

Volumn 413, Issue 17-18, 2012, Pages 1387-1390

  Hartmann, B ^a  

^a Klinik für Innere Medizin I   (Germany)

Author keywords

Everolimus; Kidney transplantation; MTOR inhibitor; Pharmacodynamic monitoring; Rapamycin; Sirolimus

Indexed keywords

BIOLOGICAL MARKER; CYTARABINE; ETOPOSIDE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOXANTRONE; RAPAMYCIN; S6 KINASE; TACROLIMUS; TEMSIROLIMUS;

ANEMIA; BREAST CANCER; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FLUORESCENCE ACTIVATED CELL SORTING; GRAFT REJECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; KAPOSI SARCOMA; KIDNEY GRAFT REJECTION; LEUKOPENIA; NONHUMAN; PHARMACODYNAMIC MONITORING; PRIORITY JOURNAL; PROTEINURIA; REVIEW; THROMBOCYTOPENIA; TUMOR REGRESSION; WESTERN BLOTTING; WOUND HEALING IMPAIRMENT;

ANIMALS; BIOLOGICAL MARKERS; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA;

MAMMALIA;

EID: 84862772241     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.03.023     Document Type: Review

References (31)

1. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
2. Loewith R., Jacinto E., Wullschleger S., et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002, 10:457-468.
3. Martel R.R., Klicius J., Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977, 55:48-51.
4. Hara K., Maruki Y., Long X., et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002, 110:177-189.
5. Kim D.H., Sarbassov D.D., Ali S.M., et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002, 110:163-175.
6. Reinhard C., Fernandez A., Lamb N.J., Thomas G. Nuclear localization of p85s6k: functional requirement for entry into S phase. EMBO J 1994, 13:1557-1565.
7. Franco R., Rosenfeld M.G. Hormonally inducible phosphorylation of a nuclear pool of ribosomal protein S6. J Biol Chem 1990, 265:4321-4325.
8. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18:1926-1945.
9. Morales J.M., Wramner L., Kreis H., et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002, 2:436-442.
10. Pearce L.R., Sommer E.M., Sakamoto K., Wullschleger S., Alessi D.R. Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney. Biochem J 2011, 436:169-179.
11. Borders E.B., Bivona C., Medina P.J. Mammalian target of rapamycin: biological function and target for novel anticancer agents. Am J Health Syst Pharm 2010, 67:2095-2106.
12. Campistol J.M., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006, 17:581-589.
13. Ruiz J.C., Campistol J.M., Sánchez-Fructuoso A., et al. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 2006, 21:3252-3257.
14. Ekberg H., Tedesco-Silva H., Demirbas A., Vítko S., Nashan B., Gürkan A. N Engl J Med 2007, 357:2562-2575.
15. Merkel S., Mogilevskaja N., Mengel M., Haller H., Schwarz A. Side effects of sirolimus. Transplant Proc 2006, 38:714-715.
16. Dambrin C., Klupp J., Morris R.E. Pharmacodynamics of immunosuppressive drugs. Curr Opin Immunol 2000, 12:557-562.
17. Gallant H.L., Yatscoff R.W. P70 S6 kinase assay: a pharmacodynamic monitoring strategy for rapamycin; assay development. Transplant Proc 1996, 28:3058-3061.
18. Chung J., Kuo C.J., Crabtree G.R., Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 1992, 69:1227-1236.
19. Garcia-Paramio P., Cabrerizo Y., Bornancin F., Parker P.J. The broad specificity of dominant inhibitory protein kinase C mutants infers a common step in phosphorylation. Biochem J 1998, 333:631-636.
20. Pearson R.B., Dennis P.B., Han J.W., et al. The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. EMBO J 1995, 14:5279-5287.
21. Dennis P.B., Pullen N., Kozma S.C., Thomas G. The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Mol Cell Biol 1996, 16:6242-6251.
22. Seufferlein T., Rozengurt E. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res 1996, 56:3895-3897.
23. Peralba J.M., DeGraffenried L., Friedrichs W., et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003, 9:2887-2892.
24. Hartmann B., Schmid G., Graeb C., et al. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy. Kidney Int 2005, 68:2593-2598.
25. Di Paolo S., Teutonico A., Ranieri E., Gesualdo L., Schena P.F. Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma. Am J Kidney Dis 2007, 49:462-470.
26. Leogrande D., Teutonico A., Ranieri E., et al. Monitoring biological action of rapamycin in renal transplantation. Am J Kidney Dis 2007, 50:314-325.
27. Dekter H.E., Romijn F.P., Temmink W.P., van Pelt J., de Fijter J.W., Smit N.P. A spectrophotometric assay for routine measurement of mammalian target of rapamycin activity in cell lysates. Anal Biochem 2010, 403:79-87.
28. Krutzik P.O., Trejo A., Schulz K.R., Nolan G.P. Phospho flow cytometry methods for the analysis of kinase signaling in cell lines and primary human blood samples. Methods Mol Biol 2011, 699:179-202.
29. Dieterlen M-T., Bittner H.B., Klein S., Salisch S., Mittag A., Tárnok A., Dhein S., Mohr F.W., Barten M.J. Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood. Cytometry Part B 2012, 00B:000-000.
30. Perl A.E., Kasner M.T., Shank D., Luger S.M., Carroll M. Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Clin Cancer Res 2012, 18:1716-1725.
31. Weichart T., Säemann M.D. The multiple facets of mTOR in immunity. Trends Immunol 2009, 30:218-226.